Valeant
Former Valeant executive and Philidor CEO charged with fraud
November 18, 2016Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud
Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …
Valeant’s tough year gets worse with Q3 loss of $1.22 billion
November 9, 2016Research and Development Q3, Valeant, loss
It’s easy to say that Valeant hasn’t had a great year so far. Unfortunately for those concerned, the outlook for …
Hard times continue for Valeant as ex-CEO investigated for fraud
November 1, 2016Manufacturing and Production CEO, Valeant, Valeant Pharmaceuticals, accounting, fraud
Valeant Pharmaceuticals continues to have a tough time after Bloomsberg broke the story of how former CEO J. Michael Pearson …
Concordia founder resigns and will step down once replacement found
October 25, 2016Manufacturing and Production CEO, Concordia, Mark Thompson, Valeant
Concordia International Corp., the Ontario-based company, has announced that its founder, Chairman and Chief Executive Officer, Mark Thompson, will leave …
Cipla receives FDA approval for generic version of Valeant antidepressant
August 30, 2016Manufacturing and Production, Sales and Marketing Cipla, FDA, Valeant, Wellbutrin
Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the …
Valeant appoints new executive VP of finance and CFO
August 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Valeant, appointment
Valeant has announced the appointment of Paul S. Herendeen as executive vice president, who will also take over as chief …
Former shareholders sue Valeant, alleging “vast fraud”
August 19, 2016Medical Communications, Sales and Marketing Valeant, fraud, lawsuit, t rowe price
Valeant Pharmaceuticals has confirmed that it is being sued by one its former largest shareholders, T Rowe Price, who claim …
Valeant under criminal investigation
August 11, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, investigation
Valeant Pharmaceuticals International is currently under investigation by the US attorney’s office in Manhattan over suspicions that the firm intentionally …
Valeant stock rises despite weak Q2 results
August 10, 2016Research and Development, Sales and Marketing Valeant, financial results
Valeant Pharmaceuticals’ share price in pre-market trading has risen 7.44% to $24.12 in the wake of its Q2 results announcement. …
Management shake-up at Valeant as Papa expands senior team
August 9, 2016Manufacturing and Production, Sales and Marketing Valeant, joseph papa, management, shake up
Joseph Papa continues to remodel the plagued Valeant Pharmaceuticals, as a senior management shake-up has seen several new arrivals and …
Valeant receives complete response letter from FDA on glaucoma drug
July 22, 2016Medical Communications, Sales and Marketing FDA, Glaucoma, Valeant
Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA rejecting their new drug application …
FDA panel unanimously recommends approval of Valeant’s brodalumab with conditions
July 20, 2016Research and Development, Sales and Marketing FDA, Valeant, brodalumab
Valeant has announced that the US Food and Drug Administration’s (FDA) dermatologic and ophthalmic drugs advisory committee has recommended brodalumab …
Valeant’s psoriasis drug “difficult to assess”, according to FDA staff
July 18, 2016Research and Development, Sales and Marketing FDA, Valeant, psoriasis
Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …
AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront
July 1, 2016Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Deals, Licencing, Loe Pharna, Valeant, drug development
UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an …
Valeant plots significant investment in Canadian operations
June 20, 2016Manufacturing and Production, Sales and Marketing Canada, Valeant, manufacturing
Valeant Pharmaceuticals (NYSE: VRX) has announced that it plans to expand its Canadian operations with a $27.5 million expansion of …
Latest content
FibroFind appoints Lee Borthwick as CEO
